AG
ELV icon

Aperio Group’s Elevance Health ELV Stock Holding History

Aperio Group’s Portfolio ELV Stock Details ELV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$84.8M Buy
264,173
+6,955
+3% +$2.13M 0.25% 64
2020
Q3 		$69.1M Sell
257,218
-4,325
-2% -$1.16M 0.23% 72
2020
Q2 		$68.8M Sell
261,543
-13,486
-5% -$3.6M 0.25% 70
2020
Q1 		$62.4M Sell
275,029
-2,526
-0.9% -$688K 0.28% 64
2019
Q4 		$83.8M Sell
277,555
-13,087
-5% -$3.6M 0.3% 58
2019
Q3 		$69.8M Sell
290,642
-11,724
-4% -$3.21M 0.28% 66
2019
Q2 		$85.3M Sell
302,366
-11,748
-4% -$3.21M 0.35% 50
2019
Q1 		$90.1M Buy
314,114
+17,389
+6% +$5.03M 0.39% 50
2018
Q4 		$77.9M Buy
296,725
+10,282
+4% +$2.83M 0.39% 42
2018
Q3 		$78.5M Buy
286,443
+811
+0.3% +$211K 0.35% 54
2018
Q2 		$68M Sell
285,632
-9,560
-3% -$2.21M 0.32% 54
2018
Q1 		$64.9M Buy
295,192
+9,259
+3% +$2.18M 0.32% 58
2017
Q4 		$64.3M Buy
285,933
+18,180
+7% +$3.87M 0.33% 58
2017
Q3 		$50.8M Buy
267,753
+21,037
+9% +$4M 0.29% 68
2017
Q2 		$46.4M Buy
246,716
+31,577
+15% +$5.67M 0.28% 71
2017
Q1 		$35.6M Buy
215,139
+22,723
+12% +$3.61M 0.24% 90
2016
Q4 		$27.7M Sell
192,416
-8,485
-4% -$1.14M 0.21% 101
2016
Q3 		$25.2M Sell
200,901
-17,339
-8% -$2.24M 0.18% 120
2016
Q2 		$28.7M Buy
218,240
+11,600
+6% +$1.59M 0.22% 104
2016
Q1 		$28.7M Buy
206,640
+3,713
+2% +$496K 0.25% 93
2015
Q4 		$28.3M Buy
202,927
+39,489
+24% +$5.44M 0.26% 85
2015
Q3 		$22.9M Buy
163,438
+21,602
+15% +$3.25M 0.23% 99
2015
Q2 		$23.3M Buy
141,836
+9,539
+7% +$1.52M 0.24% 92
2015
Q1 		$20.4M Buy
132,297
+7,129
+6% +$1.01M 0.23% 99
2014
Q4 		$15.7M Buy
125,168
+1,509
+1% +$186K 0.19% 121
2014
Q3 		$14.8M Buy
123,659
+17,521
+17% +$2.01M 0.2% 122
2014
Q2 		$11.4M Buy
106,138
+8,083
+8% +$833K 0.17% 156
2014
Q1 		$9.76M Buy
+98,055
New +$8.87M 0.14% 179
2013
Q4 		– Sell
-84,721
Closed -$7.53M – 192
2013
Q3 		$7.08M Buy
84,721
+9,273
+12% +$795K 0.14% 176
2013
Q2 		$6.17M Buy
+75,448
New +$5.65M 0.15% 157

Other funds holding ELV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $39.9B AUM 29.7% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Aperio Group's ELV Position: Q4 2020 in Review

Aperio Group increased its Elevance Health (ELV) stake by 2.7% in Q4 2020, buying an estimated $2.13M and bringing the position to 264,173 shares worth $84.8M. The position accounts for 0.25% of the portfolio, ranked #64.

Aperio Group first reported a position in ELV in Q2 2013 and has held it in 30 quarters since. The position peaked at $90.1M in Q1 2019. 1,171 funds tracked by Wall St. Rank hold ELV as of Q4 2020.

  • Aperio Group held 264,173 shares of Elevance Health worth $84.8M as of Q4 2020.
  • Aperio Group bought 6,955 Elevance Health shares in Q4 2020, an estimated $2.13M.
  • Elevance Health made up 0.25% of Aperio Group's portfolio in Q4 2020, its #64 holding.
  • Aperio Group first reported a position in Elevance Health in Q2 2013 and has held it in 30 quarters since.
  • Aperio Group's Elevance Health position peaked at $90.1M in Q1 2019.
  • 1,171 funds tracked by Wall St. Rank held Elevance Health as of Q4 2020.

Based on Aperio Group's 13F filing for Q4 2020, filed 5 Feb 2021.